Literature DB >> 31621735

Multifunctional biomimetic nanoparticles loading baicalin for polarizing tumor-associated macrophages.

Shulan Han1, Wenjie Wang2, Shengfang Wang2, Shuo Wang3, Ruijun Ju4, Zihao Pan4, Tingyuan Yang3, Guifeng Zhang3, Huimei Wang2, Lianyan Wang3.   

Abstract

Immunosuppression and immune tolerance lead tumor cells to evade immune system surveillance and weaken drug efficacy. The presence of various immunosuppressive cells in the tumor microenvironment, especially tumor-associated macrophages (TAMs), has been shown to be a driving force in tumor initiation and development. Reversion of the TAM phenotype is an effective way to induce a subsequent antitumor immune response. In this study, we developed baicalin-loaded poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles containing an antigenic peptide (Hgp 10025-33, Hgp) and a toll-like receptor 9 agonist (CpG). The nanoparticles were further coated with a galactose-inserted erythrocyte membrane, which actively targeted the TAMs. The TAM polarization and tumor treatment effectiveness of the nanoparticles were evaluated. The biomimetic nanoparticles showed enhanced cell uptake in vitro and targeted effects in vivo. In addition, compared with baicalin-loaded PLGA-NPs (B@NPs), the biomimetic nanoparticles, such as Hgp/B@NPs-CpG and NPs@RBC-Gala, significantly polarized the TAMs such that they changed from the M2 type to the M1 type both in vitro and in vivo. Subsequently, the infiltration of CD4+ T and CD8+ T cells into tumor sites after being induced by the biomimetic nanoparticles was greatly increased, which suggested a significant enhancement of the immune activation effect and T cell response. In addition, the activation of the T cells and induction of the CTL responses effectively suppressed melanoma tumor growth in vivo. In conclusion, the biomimetic nanoparticles effectively reversed the TAM phenotype from M2 to M1, which further improved the tumor immune microenvironment and promoted tumor immunotherapy. These results suggested that the TAM-targeted biomimetic drug delivery system had the potential to reverse the phenotypes of TAMs contributing to reverse the immunosuppressive tumor microenvironment and promote tumor treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31621735     DOI: 10.1039/c9nr03353j

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  8 in total

Review 1.  Latest research progress on anticancer effect of baicalin and its aglycone baicalein.

Authors:  Lin Wang; Ting Feng; Zhilian Su; Chao Pi; Yumeng Wei; Ling Zhao
Journal:  Arch Pharm Res       Date:  2022-07-31       Impact factor: 6.010

2.  Baicalin Inhibits Influenza A Virus Infection via Promotion of M1 Macrophage Polarization.

Authors:  Ping Geng; Haiyan Zhu; Wei Zhou; Chang Su; Mingcang Chen; Chenggang Huang; Chengjie Xia; Hai Huang; Yiou Cao; Xunlong Shi
Journal:  Front Pharmacol       Date:  2020-10-06       Impact factor: 5.810

3.  Mimicking the Endometrial Cancer Tumor Microenvironment to Reprogram Tumor-Associated Macrophages in Disintegrable Supramolecular Gelatin Hydrogel.

Authors:  Yujia Huang; Qian Feng; Huabo Jiang; Wanding Zhou; Jinhong Chen; Jie Gao; Kai Wang; Xiaoping Wan; Yongsheng Yu
Journal:  Int J Nanomedicine       Date:  2020-06-25

Review 4.  Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy.

Authors:  Xiaoling Ding; Xinchen Sun; Huihui Cai; Lei Wu; Ying Liu; Yu Zhao; Dingjingyu Zhou; Guiping Yu; Xiaorong Zhou
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

5.  Preparation of baicalin-loaded ligand-modified nanoparticles for nose-to-brain delivery for neuroprotection in cerebral ischemia.

Authors:  Xinxin Li; Shuling Li; Chun Ma; Tieshu Li; Lihua Yang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

6.  Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application.

Authors:  Jingjing Yan; Weidong Fei; Qianqian Song; Yao Zhu; Na Bu; Li Wang; Mengdan Zhao; Xiaoling Zheng
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 7.  Revisiting the outstanding questions in cancer nanomedicine with a future outlook.

Authors:  M S Sudheesh; K Pavithran; Sabitha M
Journal:  Nanoscale Adv       Date:  2021-12-22

Review 8.  Tumor‑associated macrophages in lung cancer: Friend or foe? (Review).

Authors:  Fei Xu; Ying Wei; Zhao Tang; Baojun Liu; Jingcheng Dong
Journal:  Mol Med Rep       Date:  2020-09-17       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.